Your browser is no longer supported. Please, upgrade your browser.
Intra-Cellular Therapies, Inc.
Index- P/E- EPS (ttm)-3.20 Insider Own1.40% Shs Outstand81.36M Perf Week4.12%
Market Cap3.59B Forward P/E- EPS next Y-3.02 Insider Trans-30.14% Shs Float74.44M Perf Month-11.49%
Income-259.10M PEG- EPS next Q-1.00 Inst Own81.10% Short Float6.09% Perf Quarter-0.54%
Sales70.60M P/S50.84 EPS this Y-20.50% Inst Trans0.37% Short Ratio4.65 Perf Half Y18.06%
Book/sh5.98 P/B7.13 EPS next Y8.10% ROA-40.30% Target Price60.89 Perf Year28.03%
Cash/sh5.67 P/C7.52 EPS next 5Y- ROE-44.90% 52W Range28.40 - 55.19 Perf YTD-18.49%
Dividend- P/FCF- EPS past 5Y-2.10% ROI-35.20% 52W High-22.71% Beta1.28
Dividend %- Quick Ratio10.50 Sales past 5Y201.60% Gross Margin90.60% 52W Low50.21% ATR3.36
Employees383 Current Ratio10.70 Sales Q/Q200.00% Oper. Margin- RSI (14)49.30 Volatility7.97% 6.85%
OptionableYes Debt/Eq0.00 EPS Q/Q-19.10% Profit Margin- Rel Volume2.74 Prev Close38.87
ShortableYes LT Debt/Eq0.00 EarningsNov 09 BMO Payout- Avg Volume976.10K Price42.66
Recom1.60 SMA20-6.96% SMA500.68% SMA20011.30% Volume2,675,431 Change9.75%
Sep-23-21Initiated Needham Buy $55
Dec-15-20Initiated BofA Securities Buy $40
Dec-10-20Initiated Goldman Buy $38
Feb-20-20Initiated Evercore ISI Outperform
Jan-31-20Downgrade JP Morgan Overweight → Neutral $26
Dec-24-19Reiterated Canaccord Genuity Buy $29 → $65
Aug-12-19Initiated Jefferies Buy $16
Feb-26-18Initiated JP Morgan Overweight
Feb-08-18Initiated RBC Capital Mkts Outperform $33
Dec-15-17Initiated Canaccord Genuity Buy $31
Nov-08-17Upgrade SunTrust Hold → Buy
Sep-07-17Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17Upgrade Ladenburg Thalmann Neutral → Buy
Aug-24-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Aug-23-17Upgrade Leerink Partners Mkt Perform → Outperform
May-02-17Downgrade Leerink Partners Outperform → Mkt Perform
May-02-17Downgrade Ladenburg Thalmann Buy → Neutral
May-01-17Downgrade Piper Jaffray Overweight → Neutral
Dec-16-16Initiated Cantor Fitzgerald Overweight
Sep-29-16Reiterated RBC Capital Mkts Outperform $74 → $49
Jan-10-22 05:38PM  
Jan-07-22 04:01PM  
Jan-04-22 10:05PM  
Jan-03-22 04:01PM  
Dec-27-21 11:38PM  
Dec-24-21 09:15AM  
Dec-23-21 10:32AM  
Dec-21-21 09:18AM  
Dec-20-21 08:59AM  
Dec-14-21 06:56AM  
Dec-08-21 07:38PM  
Dec-06-21 04:01PM  
Nov-09-21 02:00PM  
Nov-02-21 08:00AM  
Nov-01-21 03:01PM  
Oct-26-21 10:26AM  
Oct-19-21 07:30PM  
Oct-18-21 08:00AM  
Oct-08-21 08:00AM  
Sep-28-21 09:28AM  
Sep-27-21 09:19AM  
Sep-22-21 08:00AM  
Sep-21-21 01:21PM  
Sep-20-21 07:30AM  
Aug-16-21 08:52AM  
Aug-13-21 04:48PM  
Aug-10-21 08:00AM  
Aug-09-21 06:00PM  
Aug-02-21 03:01PM  
Jun-19-21 02:44PM  
Jun-15-21 01:04AM  
Jun-07-21 08:00AM  
May-26-21 08:00AM  
May-10-21 03:00PM  
May-05-21 08:00AM  
May-04-21 08:00AM  
May-03-21 07:30AM  
Apr-29-21 05:06PM  
Apr-24-21 08:47AM  
Apr-23-21 03:40AM  
Apr-22-21 07:30AM  
Apr-20-21 07:00AM  
Apr-12-21 07:30AM  
Feb-25-21 08:30PM  
Feb-24-21 10:42AM  
Feb-22-21 08:00AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
Feb-10-21 02:58AM  
Jan-21-21 08:00AM  
Jan-06-21 08:40AM  
Jan-05-21 08:00AM  
Dec-29-20 08:00AM  
Dec-14-20 01:58PM  
Dec-09-20 08:00AM  
Dec-01-20 05:32AM  
Nov-30-20 08:00AM  
Nov-12-20 06:09AM  
Nov-09-20 06:00PM  
Nov-07-20 07:04AM  
Nov-04-20 08:00AM  
Oct-26-20 08:18AM  
Oct-04-20 06:20AM  
Oct-02-20 07:00AM  
Oct-01-20 04:30PM  
Sep-22-20 11:08AM  
Sep-15-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 08:42AM  
Sep-10-20 08:30PM  
Sep-09-20 05:12PM  
Sep-03-20 08:12AM  
Aug-10-20 05:30PM  
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Durgam Suresh K.Chief Medical OfficerJan 18Sale42.036,223261,55323,104Jan 20 04:07 PM
Durgam Suresh K.Chief Medical OfficerJan 10Sale40.766,870280,02029,327Jan 11 08:08 PM
Neumann MarkEVP, Chief Commercial OfficerJan 10Sale40.7820,948854,25545,339Jan 11 08:06 PM
Halstead MichaelEVP and General CounselJan 10Sale40.7719,639800,7740Jan 11 08:04 PM
Hineline Lawrence J.SVP of Finance CFOJan 10Sale40.7619,639800,4200Jan 11 08:02 PM
Mates SharonChairman, President & CEOJan 10Sale40.7841,8961,708,4291,094,467Jan 11 08:00 PM
Hineline Lawrence J.SVP of Finance CFODec 21Option Exercise16.81175,0002,941,951175,000Dec 23 07:00 PM
Halstead MichaelEVP and General CounselDec 21Option Exercise16.38176,8632,897,494176,863Dec 23 07:02 PM
Halstead MichaelEVP and General CounselDec 21Sale47.56176,8638,412,2780Dec 23 07:02 PM
Hineline Lawrence J.SVP of Finance CFODec 21Sale47.59175,0008,328,6640Dec 23 07:00 PM
Neumann MarkEVP, Chief Commercial OfficerOct 18Sale40.8613,448549,55145,339Oct 19 04:26 PM
Mates SharonChairman, President & CEOOct 18Sale40.008,192327,6801,094,467Oct 18 06:00 PM
Mates SharonChairman, President & CEOOct 15Option Exercise2.841,0753,0531,102,659Oct 18 06:00 PM
Mates SharonChairman, President & CEOOct 15Sale40.0040,3921,615,6801,101,584Oct 18 06:00 PM
Mates SharonChairman, President & CEOOct 14Sale40.001,41656,6401,141,976Oct 18 06:00 PM
Mates SharonChairman, President & CEOAug 23Option Exercise2.8410,00028,4001,143,392Aug 24 04:06 PM
MARCUS JOEL SDirectorJun 14Option Exercise38.3520,000767,00067,269Jun 15 05:02 PM
MARCUS JOEL SDirectorJun 14Sale42.2718,289773,07648,980Jun 15 05:02 PM
Alafi Christopher DDirectorMay 28Sale40.1238,8431,558,38195,000May 28 06:00 PM
Alafi Christopher DDirectorMay 27Sale40.018,482339,365133,843May 28 06:00 PM
Alafi Christopher DDirectorMay 24Sale40.4726,5751,075,490142,325May 25 06:02 PM
Alafi Christopher DDirectorMay 21Sale40.001,10044,000168,900May 25 06:02 PM
MARCUS JOEL SDirectorMar 02Option Exercise26.5820,000531,60087,519Mar 04 05:43 PM
MARCUS JOEL SDirectorMar 02Sale34.9315,250532,68272,269Mar 04 05:43 PM
Durgam Suresh K.Chief Medical OfficerFeb 19Sale39.252,734107,31023,104Feb 22 08:09 PM
Neumann MarkEVP, Chief Commercial OfficerFeb 19Sale39.225,184203,30845,339Feb 22 08:07 PM
Hineline Lawrence J.SVP of Finance CFOFeb 19Sale39.2310,442409,6250Feb 22 08:05 PM
Halstead MichaelEVP and General CounselFeb 19Sale39.2411,139437,1330Feb 22 08:03 PM
Mates SharonChairman, President & CEOFeb 19Sale39.2327,8471,092,4361,133,392Feb 22 08:01 PM